Pannexin-I/P2X 7 purinergic receptor channels mediate the release of cardioprotectants induced by ischemic pre- and postconditioning

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 15, Issue 2, 2010, Pages 190-195

  Vessey, Donald A ^a,b   Li, Luyi ^a   Kelley, Michael ^a  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adenosine; Brilliant blue G; Carbenoxolone; Cardioprotection; Ischemia reperfusion injury; P2X7 receptor; Pannexin 1; Postconditioning; Preconditioning; Sphingosine 1 phosphate

Indexed keywords

ADENOSINE; ADENOSINE TRIPHOSPHATE; BRILLIANT BLUE; CARBENOXOLONE; GAP JUNCTION PROTEIN; MEFLOQUINE; PANNEXIN I; PANNEXIN I PURINERGIC P2X7 RECEPTOR CHANNEL; PROTEIN; PURINERGIC P2X RECEPTOR; PURINERGIC P2X7 RECEPTOR; PURINERGIC P2Y RECEPTOR; SPHINGOSINE 1 PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REPERFUSION INJURY;

ADENOSINE; ADENOSINE TRIPHOSPHATE; ANIMALS; CARBENOXOLONE; CONNEXINS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; LYSOPHOSPHOLIPIDS; MEFLOQUINE; MYOCARDIAL REPERFUSION INJURY; NERVE TISSUE PROTEINS; RATS; RECEPTORS, PURINERGIC P2; ROSANILINE DYES; SPHINGOSINE;

EID: 77951928146     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248409360356     Document Type: Article

References (33)

1. Jennings RB, Reimer KA The cell biology of acute myocardial ischemia. Annu Revs Med. 1991 ; 42: 225-246.
2. Buja LM, Entman ML Modes of myocardial cell injury and cell death in ischemic heart disease. Circulation. 1998 ; 98 (14). 1355-1357.
3. Hansen PR Myocardial reperfusion injury: experimental evidence and clinical relevance. Eur Heart J. 1995 ; 16 (6). 734-740.
4. Maxwell SR, Lip GY Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic options. Int J Cardiol. 1997 ; 58 (2). 95-117.
5. Murry CE, Richard VJ, Reimer KA, Jennings RB Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ Res. 1990 ; 66 (4). 913-931.
6. Deutsch E., Berger M., Kussmaul WG, Hirshfeld JW Jr, Hermann HC, Laskey WK Adaptation to ischemia during percutaneous transluminal coronary angioplasty: clinical hemodynamic, and metabolic features. Circulation. 1990 ; 82 (6). 2044-2051.
7. Zhao Z. - Q. Vinten-Johansen J. Postconditioning: reduction of reperfusion-induced injury. Cardiovasc Res. 2006 ; 70 (2). 200-211.
8. Gross ER, Gross GJ Ischemic preconditioning and myocardial infarction: an update and perspective. Drug Discov Today Dis Mech. 2007 ; 4 (3). 165-174.
9. Murphy E., Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev. 2008 ; 88 (2). 581-609.
10. Vessey DA, Li L., Honbo N., Karliner JS Sphingosine 1-phosphate is an important endogenous cardioprotectant released by ischemic pre- and post-conditioning. Am J Physiol Heart Circ Physiol. 2009 ; 297 (4). H1429 - H1435.
11. Hausenloy DJ, Tsang A., Yellon DM The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med. 2004 ; 15 (2). 69-75.
12. Morrison RR, Tan XL, Ledent C., Mustafa SJ, Hofmann PA Targeted deletion of A2A adenosine receptors attenuates the protective effects of myocardial postconditioning. Am J Physiol Heart Circ Physiol. 2007 ; 293 (4). H2523 - H2529.
13. Dahl G., Locovei S. Pannexin: to gap or not to gap, is that a question? IUBMB Life. 2006 ; 58 (7). 409-419.
14. Iglesias R., Dahl G., Spray DC, Scemes E. Pannexin1: the molecular substrate of astrocyte"hemichannels.g?g? J Neurosci. 2009 ; 29 (21). 7092-7097.
15. Pelegrin P., Surprenant A. The P2X7 receptor-pannexin connection to dye uptake and IL-1?2 release. Purinergic Signal. 2009 ; 5 (2). 129-137.
16. North RA Molecular physiology of P2X receptors. Physiol Rev. 2002 ; 82 (4). 1013-1067.
17. Baranova A., Ivanov D., Petrash N., et al. The mammalian pannexin family is homologous to the invertebrate innexin gap junction proteins. Genomics. 2004 ; 83 (4). 706-716.
18. Ray A., Zoidl G., Weickert S., Wahle P., Dermietzel R. Site-specific and developmental expression of pannexin1 in the mouse nervous system. Eur J Neurosci. 2005 ; 21 (12). 3277-3290.
19. Musa H., Tellez JO, Chandler NJ, et al. P2 purinergic receptro mRNA in rat and human sinoatrial node and other heart regions. Naunyn-Schmiedebergs Arch Pharmacol. 2009 ; 379 (6). 541-549.
20. Vessey DA, Kelley M., Li L., et al. Role of sphingosine kinase activity in protection of heart against ischemia reperfusion injury. Med Sci Monit. 2006 ; 12 (10). BR318 - BR324.
21. Vessey DA, Li L., Kelley M., Karliner JS Sphingosine can pre-and post-condition heart and utilizes a different mechanism from sphingosine 1-phosphate. J Biochem Mol Toxicol. 2008 ; 22 (2). 113-118.
22. Vessey DA, Kelley M., Li L., Huang Y. Sphingosine protects aging hearts from ischemia/reperfusion injury. Superiority to sphingosine 1-phosphate and ischemic pre- and post-conditioning. Oxid Med Cell Longev. 200 9; 2 (3). 146-151.
23. Bruzzone R., Barbe MT, Jakob NJ, Monyer H. Pharmacological properties of homomeric and heteromeric pannexin hemichannels expressed in Xenopus oocytes. J Neurochem. 2005 ; 92 (5). 1033-1043.
24. Ma W., Hui H., Pelegrin P., Surprenant A. Pharmacological characterization of pannexin-1 currents expressed in mammalian cells. J Pharmacol Exp Ther. 2009 ; 328 (2). 409-418.
25. Iglesias R., Locovei S., Roque A., et al. P2X7 receptor-pannexin1 complex: pharmacology and signaling. Am J Physiol Cell Physiol. 2008 ; 295 (3). C752 - C760.
26. Jiang L., Mackenzie AB, North RA, Surprenant A. Brilliant blue G selectively blocks ATP-gated rat P2X7 receptors. Mol Pharmacol. 2000 ; 58 (1). 82-88.
27. von Kugelgen I. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol Ther. 2006 ; 110 (3). 415-432.
28. Evans WH, Leybaert L. Mimetic peptides as blockers of connexin channel-facilitated intercellular communication. Cell Commun Adhes. 2007 ; 14 (6). 265-273.
29. van Veen TAB, van Rijen HVM, Opthof T. Cardiac gap junction channels: modulation of expression and channel properties. Cardiovasc Res. 2001 ; 51 (2). 217-229.
30. Srinivas M., Hopperstad MG, Spray DC Quinine blocks specific gap junction channel subtypes. Proc Natl Acad Sci U S A. 2001 ; 98 (19). 10942-10947.
31. Cruikshank SJ, Hopperstad M., Younger M., Connors BW, Spray DC Potent block of Cx36 and Cx50 gap junction channels by mefloquine. Proc Natl Acad Sci U S A. 2004 ; 101 (33). 12364-12369.
32. Thompson RJ, Zhou N., MacVicar BA Ischemia opens neuronal gap junction hemichannels. Science. 2006 ; 312 (5775). 924-927.
33. Locovei S., Scemes E., Qui F., Spray DC, Dahl G. Pannexin 1 is part of the pore forming unit of the P2X7 receptor death complex. FEBS Lett. 2007 ; 581 (3). 483-488.